Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.67.

Several equities research analysts recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 price target on shares of Exelixis in a report on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, September 18th. UBS Group assumed coverage on shares of Exelixis in a research report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price target on the stock. JMP Securities restated a “market outperform” rating and set a $29.00 price objective on shares of Exelixis in a research report on Friday, September 20th. Finally, Truist Financial reiterated a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a report on Thursday, August 8th.

Exelixis Stock Performance

Shares of EXEL stock opened at $26.24 on Friday. Exelixis has a fifty-two week low of $18.64 and a fifty-two week high of $27.83. The firm has a market capitalization of $7.96 billion, a P/E ratio of 41.00, a PEG ratio of 0.56 and a beta of 0.54. The stock’s fifty day moving average is $25.79 and its two-hundred day moving average is $23.55.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. The firm had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. On average, equities analysts forecast that Exelixis will post 1.59 earnings per share for the current year.

Insider Activity

In related news, Director Maria C. Freire sold 8,250 shares of the stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the transaction, the director now owns 91,007 shares of the company’s stock, valued at approximately $2,417,145.92. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Exelixis news, Director Maria C. Freire sold 8,250 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total transaction of $219,120.00. Following the sale, the director now directly owns 91,007 shares in the company, valued at approximately $2,417,145.92. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 327,858 shares of company stock valued at $8,640,129. 2.85% of the stock is currently owned by corporate insiders.

Institutional Trading of Exelixis

Large investors have recently made changes to their positions in the company. Fisher Asset Management LLC grew its holdings in Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares in the last quarter. Rise Advisors LLC acquired a new position in shares of Exelixis during the first quarter worth $28,000. Park Place Capital Corp purchased a new position in Exelixis in the second quarter valued at $45,000. GAMMA Investing LLC raised its stake in Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its holdings in Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,746 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.